MARKET NEWS

 

Salarius Pharmaceuticals Receives $2.7 Million in Payment From the Cancer Prevention & Research Institute of Texas
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar & Vaginal Atrophy
Soligenix Announces Accelerated Publication Demonstrating Efficacy & Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients With Ulcerative Proctitis & Ulcerative Proctosigmoiditis
New BD Cell Analyzer Includes Spectral Analysis Capabilities
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery & Development & Advances in Neuroscience Portfolio 

  FEATURED EDITORIAL

 

  COMPANY PROFILE

HCmed Innovations focuses on the development of drug-device combination products for inhalation therapy. It develops and manufactures portable vibrating mesh nebulizers that offer a mature customization platform, aiming to enhance drug delivery. This technology enables efficient and reliable nebulization of different types of medication, ranging from small molecule synthetics to large molecule biologics, as either solutions, suspensions or even difficult-to-deliver high viscosity drugs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy

Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy

Novigenix SA recently announced release of the article Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Immune checkpoint inhibitors (ICIs) have become….

Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline

Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline

Genetron Holdings Limited recently announced a partnership with IMPACT Therapeutics in which the two parties will cooperate together on research and development for synthetic lethal inhibitors that are based on….

Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis

Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis

Evelo Biosciences, Inc. recently announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the….

ESCP Models - Hepatitis C Medications (Part 1)

ESCP Models - Hepatitis C Medications (Part 1)

In a series of four articles earlier this year, the principles of the ESCP Analysis process were outlined with a few simple to understand examples. To better explain the application of the process, I have summarized the evolution of Hepatitis C (HCV) treatment from naked Interferon alpha treatment through to the latest….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 13 – Bioavailability
October 20 – Capsules